APO Research
Talk to an analyst

APO RESEARCH · REPORT

Nimodipine Sustained Release Tablets

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Nimodipine Sustained Release Tablets Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

31 December 2025195 pages

Choose your research edition.

Industry ResearchNimodipine Sustained Release Tablets Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Nimodipine Sustained Release Tablets Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Nimodipine Sustained Release Tablets Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Nimodipine Sustained Release Tablets Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Nimodipine Sustained Release Tablets Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Nimodipine Sustained Release Tablets market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Nimodipine Sustained Release Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Nimodipine Sustained Release Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Nimodipine Sustained Release Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Nimodipine Sustained Release Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Nimodipine Sustained Release Tablets include Arbor Pharmaceuticals, Bayer Vital, Bionpharma, Heritage Pharmaceuticals, Pharmaceutics International, Sofgen Pharmaceuticals, Wuhan HITECK Biopharmaceutical, Sihuan Pharmaceutical and Jiangsu Kanion Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Nimodipine Sustained Release Tablets market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Nimodipine Sustained Release Tablets and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Nimodipine Sustained Release Tablets sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Nimodipine Sustained Release Tablets market size, projected growth trends, production technologies, key applications, and end-use industries.

Nimodipine Sustained Release Tablets Segment by Company

Arbor Pharmaceuticals

Bayer Vital

Bionpharma

Heritage Pharmaceuticals

Pharmaceutics International

Sofgen Pharmaceuticals

Wuhan HITECK Biopharmaceutical

Sihuan Pharmaceutical

Jiangsu Kanion Pharmaceutical

Qilu Pharmaceutical

Shandong Yunmen Pharmaceutical

Yabao Pharmaceutical Group

Nimodipine Sustained Release Tablets Segment by Type

30mg/Piece

60mg/Piece

Others

Nimodipine Sustained Release Tablets Segment by Application

Hospital

Pharmacy

Others

Nimodipine Sustained Release Tablets Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nimodipine Sustained Release Tablets market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Nimodipine Sustained Release Tablets and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nimodipine Sustained Release Tablets.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Nimodipine Sustained Release Tablets market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Nimodipine Sustained Release Tablets manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Nimodipine Sustained Release Tablets in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Nimodipine Sustained Release Tablets in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Nimodipine Sustained Release Tablets Industry Trends Table 2. Nimodipine Sustained Release Tablets Industry Drivers Table 3. Nimodipine Sustained Release Tablets Industry Opportunities and Challenges Table 4. Nimodipine Sustained Release Tablets Industry Restraints Table 5. Global Nimodipine Sustained Release Tablets Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Nimodipine Sustained Release Tablets Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Nimodipine Sustained Release Tablets Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Nimodipine Sustained Release Tablets Sales Market Share by Manufacturers Table 9. Global Nimodipine Sustained Release Tablets Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Nimodipine Sustained Release Tablets Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Nimodipine Sustained Release Tablets Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Nimodipine Sustained Release Tablets Manufacturers, Product Type & Application Table 13. Global Nimodipine Sustained Release Tablets Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Nimodipine Sustained Release Tablets by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of 30mg/Piece Table 17. Major Manufacturers of 60mg/Piece Table 18. Major Manufacturers of Others Table 19. Global Nimodipine Sustained Release Tablets Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Nimodipine Sustained Release Tablets Sales by Type (2021-2026) & (K Units) Table 21. Global Nimodipine Sustained Release Tablets Sales by Type (2027-2032) & (K Units) Table 22. Global Nimodipine Sustained Release Tablets Sales Market Share by Type (2021-2026) Table 23. Global Nimodipine Sustained Release Tablets Sales Market Share by Type (2027-2032) Table 24. Global Nimodipine Sustained Release Tablets Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global Nimodipine Sustained Release Tablets Revenue by Type (2021-2026) & (K Units) Table 26. Global Nimodipine Sustained Release Tablets Revenue by Type (2027-2032) & (K Units) Table 27. Global Nimodipine Sustained Release Tablets Revenue Market Share by Type (2021-2026) Table 28. Global Nimodipine Sustained Release Tablets Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Hospital Table 30. Major Manufacturers of Pharmacy Table 31. Major Manufacturers of Others Table 32. Global Nimodipine Sustained Release Tablets Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Nimodipine Sustained Release Tablets Sales by Application (2021-2026) & (K Units) Table 34. Global Nimodipine Sustained Release Tablets Sales by Application (2027-2032) & (K Units) Table 35. Global Nimodipine Sustained Release Tablets Sales Market Share by Application (2021-2026) Table 36. Global Nimodipine Sustained Release Tablets Sales Market Share by Application (2027-2032) Table 37. Global Nimodipine Sustained Release Tablets Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Nimodipine Sustained Release Tablets Revenue by Application (2021-2026) & (K Units) Table 39. Global Nimodipine Sustained Release Tablets Revenue by Application (2027-2032) & (K Units) Table 40. Global Nimodipine Sustained Release Tablets Revenue Market Share by Application (2021-2026) Table 41. Global Nimodipine Sustained Release Tablets Revenue Market Share by Application (2027-2032) Table 42. Global Nimodipine Sustained Release Tablets Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Nimodipine Sustained Release Tablets Sales by Region (2021-2026) & (K Units) Table 44. Global Nimodipine Sustained Release Tablets Sales Market Share by Region (2021-2026) Table 45. Global Nimodipine Sustained Release Tablets Sales Forecasted by Region (2027-2032) & (K Units) Table 46. Global Nimodipine Sustained Release Tablets Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Nimodipine Sustained Release Tablets Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 48. North America Nimodipine Sustained Release Tablets Sales by Country (2021-2026) & (K Units) Table 49. North America Nimodipine Sustained Release Tablets Sales by Country (2027-2032) & (K Units) Table 50. Europe Nimodipine Sustained Release Tablets Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. Europe Nimodipine Sustained Release Tablets Sales by Country (2021-2026) & (K Units) Table 52. Europe Nimodipine Sustained Release Tablets Sales by Country (2027-2032) & (K Units) Table 53. Asia Pacific Nimodipine Sustained Release Tablets Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Asia Pacific Nimodipine Sustained Release Tablets Sales by Country (2021-2026) & (K Units) Table 55. Asia Pacific Nimodipine Sustained Release Tablets Sales by Country (2027-2032) & (K Units) Table 56. South America, Middle East and Africa Nimodipine Sustained Release Tablets Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. South America, Middle East and Africa Nimodipine Sustained Release Tablets Sales by Country (2021-2026) & (K Units) Table 58. South America, Middle East and Africa Nimodipine Sustained Release Tablets Sales by Country (2027-2032) & (K Units) Table 59. Global Nimodipine Sustained Release Tablets Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Nimodipine Sustained Release Tablets Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Nimodipine Sustained Release Tablets Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Nimodipine Sustained Release Tablets Revenue Market Share by Region (2021-2026) Table 63. Global Nimodipine Sustained Release Tablets Revenue Market Share by Region (2027-2032) Table 64. Arbor Pharmaceuticals Company Information Table 65. Arbor Pharmaceuticals Business Overview Table 66. Arbor Pharmaceuticals Nimodipine Sustained Release Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Arbor Pharmaceuticals Nimodipine Sustained Release Tablets Product Portfolio Table 68. Arbor Pharmaceuticals Recent Development Table 69. Bayer Vital Company Information Table 70. Bayer Vital Business Overview Table 71. Bayer Vital Nimodipine Sustained Release Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Bayer Vital Nimodipine Sustained Release Tablets Product Portfolio Table 73. Bayer Vital Recent Development Table 74. Bionpharma Company Information Table 75. Bionpharma Business Overview Table 76. Bionpharma Nimodipine Sustained Release Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Bionpharma Nimodipine Sustained Release Tablets Product Portfolio Table 78. Bionpharma Recent Development Table 79. Heritage Pharmaceuticals Company Information Table 80. Heritage Pharmaceuticals Business Overview Table 81. Heritage Pharmaceuticals Nimodipine Sustained Release Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Heritage Pharmaceuticals Nimodipine Sustained Release Tablets Product Portfolio Table 83. Heritage Pharmaceuticals Recent Development Table 84. Pharmaceutics International Company Information Table 85. Pharmaceutics International Business Overview Table 86. Pharmaceutics International Nimodipine Sustained Release Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Pharmaceutics International Nimodipine Sustained Release Tablets Product Portfolio Table 88. Pharmaceutics International Recent Development Table 89. Sofgen Pharmaceuticals Company Information Table 90. Sofgen Pharmaceuticals Business Overview Table 91. Sofgen Pharmaceuticals Nimodipine Sustained Release Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Sofgen Pharmaceuticals Nimodipine Sustained Release Tablets Product Portfolio Table 93. Sofgen Pharmaceuticals Recent Development Table 94. Wuhan HITECK Biopharmaceutical Company Information Table 95. Wuhan HITECK Biopharmaceutical Business Overview Table 96. Wuhan HITECK Biopharmaceutical Nimodipine Sustained Release Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Wuhan HITECK Biopharmaceutical Nimodipine Sustained Release Tablets Product Portfolio Table 98. Wuhan HITECK Biopharmaceutical Recent Development Table 99. Sihuan Pharmaceutical Company Information Table 100. Sihuan Pharmaceutical Business Overview Table 101. Sihuan Pharmaceutical Nimodipine Sustained Release Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Sihuan Pharmaceutical Nimodipine Sustained Release Tablets Product Portfolio Table 103. Sihuan Pharmaceutical Recent Development Table 104. Jiangsu Kanion Pharmaceutical Company Information Table 105. Jiangsu Kanion Pharmaceutical Business Overview Table 106. Jiangsu Kanion Pharmaceutical Nimodipine Sustained Release Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Jiangsu Kanion Pharmaceutical Nimodipine Sustained Release Tablets Product Portfolio Table 108. Jiangsu Kanion Pharmaceutical Recent Development Table 109. Qilu Pharmaceutical Company Information Table 110. Qilu Pharmaceutical Business Overview Table 111. Qilu Pharmaceutical Nimodipine Sustained Release Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Qilu Pharmaceutical Nimodipine Sustained Release Tablets Product Portfolio Table 113. Qilu Pharmaceutical Recent Development Table 114. Shandong Yunmen Pharmaceutical Company Information Table 115. Shandong Yunmen Pharmaceutical Business Overview Table 116. Shandong Yunmen Pharmaceutical Nimodipine Sustained Release Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Shandong Yunmen Pharmaceutical Nimodipine Sustained Release Tablets Product Portfolio Table 118. Shandong Yunmen Pharmaceutical Recent Development Table 119. Yabao Pharmaceutical Group Company Information Table 120. Yabao Pharmaceutical Group Business Overview Table 121. Yabao Pharmaceutical Group Nimodipine Sustained Release Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. Yabao Pharmaceutical Group Nimodipine Sustained Release Tablets Product Portfolio Table 123. Yabao Pharmaceutical Group Recent Development Table 124. Key Raw Materials Table 125. Raw Materials Key Suppliers Table 126. Nimodipine Sustained Release Tablets Distributors List Table 127. Nimodipine Sustained Release Tablets Customers List Table 128. Research Programs/Design for This Report Table 129. Authors List of This Report Table 130. Secondary Sources Table 131. Primary Sources List of Figures Figure 1. Nimodipine Sustained Release Tablets Product Image Figure 2. Global Nimodipine Sustained Release Tablets Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Nimodipine Sustained Release Tablets Market Size (2021-2032) & (US$ Million) Figure 4. Global Nimodipine Sustained Release Tablets Sales (2021-2032) & (K Units) Figure 5. Global Nimodipine Sustained Release Tablets Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Nimodipine Sustained Release Tablets Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. 30mg/Piece Image Figure 9. 60mg/Piece Image Figure 10. Others Image Figure 11. Global Nimodipine Sustained Release Tablets Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Nimodipine Sustained Release Tablets Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Nimodipine Sustained Release Tablets Sales Market Share by Type (2021-2032) Figure 14. Global Nimodipine Sustained Release Tablets Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Nimodipine Sustained Release Tablets Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Nimodipine Sustained Release Tablets Revenue Market Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Pharmacy Image Figure 19. Others Image Figure 20. Global Nimodipine Sustained Release Tablets Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Nimodipine Sustained Release Tablets Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Nimodipine Sustained Release Tablets Sales Market Share by Application (2021-2032) Figure 23. Global Nimodipine Sustained Release Tablets Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Nimodipine Sustained Release Tablets Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Nimodipine Sustained Release Tablets Revenue Market Share by Application (2021-2032) Figure 26. North America Nimodipine Sustained Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 27. North America Nimodipine Sustained Release Tablets Sales Market Share by Country (2021-2032) Figure 28. U.S. Nimodipine Sustained Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Canada Nimodipine Sustained Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Mexico Nimodipine Sustained Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Nimodipine Sustained Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Nimodipine Sustained Release Tablets Sales Market Share by Country (2021-2032) Figure 33. Germany Nimodipine Sustained Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 34. France Nimodipine Sustained Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 35. U.K. Nimodipine Sustained Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Italy Nimodipine Sustained Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Netherlands Nimodipine Sustained Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Nimodipine Sustained Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Nimodipine Sustained Release Tablets Sales Market Share by Country (2021-2032) Figure 40. China Nimodipine Sustained Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Japan Nimodipine Sustained Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 42. South Korea Nimodipine Sustained Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Southeast Asia Nimodipine Sustained Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 44. India Nimodipine Sustained Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Australia Nimodipine Sustained Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Nimodipine Sustained Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Nimodipine Sustained Release Tablets Sales Market Share by Country (2021-2032) Figure 48. Brazil Nimodipine Sustained Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South Africa Nimodipine Sustained Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Saudi Arabia Nimodipine Sustained Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Turkey Nimodipine Sustained Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Argentina Nimodipine Sustained Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 53. UAE Nimodipine Sustained Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Egypt Nimodipine Sustained Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Chile Nimodipine Sustained Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Global Nimodipine Sustained Release Tablets Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Nimodipine Sustained Release Tablets Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Nimodipine Sustained Release Tablets Revenue (2021-2032) & (US$ Million) Figure 59. North America Nimodipine Sustained Release Tablets Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Nimodipine Sustained Release Tablets Revenue (2021-2032) & (US$ Million) Figure 61. Europe Nimodipine Sustained Release Tablets Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Nimodipine Sustained Release Tablets Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Nimodipine Sustained Release Tablets Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Nimodipine Sustained Release Tablets Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Nimodipine Sustained Release Tablets Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Nimodipine Sustained Release Tablets Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Nimodipine Sustained Release Tablets Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • 30mg/Piece
  • 60mg/Piece
  • Others
Applications
  • Hospital
  • Pharmacy
  • Others
Companies covered
  • Arbor Pharmaceuticals
  • Bayer Vital
  • Bionpharma
  • Heritage Pharmaceuticals
  • Pharmaceutics International
  • Sofgen Pharmaceuticals
  • Wuhan HITECK Biopharmaceutical
  • Sihuan Pharmaceutical
  • Jiangsu Kanion Pharmaceutical
  • Qilu Pharmaceutical
  • Shandong Yunmen Pharmaceutical
  • Yabao Pharmaceutical Group

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Nimodipine Sustained Release Tablets Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Nimodipine Sustained Release Tablets Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Nimodipine Sustained Release Tablets Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Nimodipine Sustained Release Tablets Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Nimodipine Sustained Release Tablets Market Dynamics
  1. 2.1 Nimodipine Sustained Release Tablets Industry Trends
  2. 2.2 Nimodipine Sustained Release Tablets Industry Drivers
  3. 2.3 Nimodipine Sustained Release Tablets Industry Opportunities and Challenges
  4. 2.4 Nimodipine Sustained Release Tablets Industry Restraints
3 Nimodipine Sustained Release Tablets Market by Manufacturers
  1. 3.1 Global Nimodipine Sustained Release Tablets Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Nimodipine Sustained Release Tablets Sales by Manufacturers (2021-2026)
  3. 3.3 Global Nimodipine Sustained Release Tablets Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Nimodipine Sustained Release Tablets Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Nimodipine Sustained Release Tablets Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Nimodipine Sustained Release Tablets Manufacturers, Product Type & Application
  7. 3.7 Global Nimodipine Sustained Release Tablets Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Nimodipine Sustained Release Tablets Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Nimodipine Sustained Release Tablets Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Nimodipine Sustained Release Tablets Tier 1, Tier 2, and Tier 3
4 Nimodipine Sustained Release Tablets Market by Type
  1. 4.1 Nimodipine Sustained Release Tablets Type Introduction
  2. 4.1.1 30mg/Piece
  3. 4.1.2 60mg/Piece
  4. 4.1.3 Others
  5. 4.2 Global Nimodipine Sustained Release Tablets Sales by Type
  6. 4.2.1 Global Nimodipine Sustained Release Tablets Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Nimodipine Sustained Release Tablets Sales by Type (2021-2032)
  8. 4.2.3 Global Nimodipine Sustained Release Tablets Sales Market Share by Type (2021-2032)
  9. 4.3 Global Nimodipine Sustained Release Tablets Revenue by Type
  10. 4.3.1 Global Nimodipine Sustained Release Tablets Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Nimodipine Sustained Release Tablets Revenue by Type (2021-2032)
  12. 4.3.3 Global Nimodipine Sustained Release Tablets Revenue Market Share by Type (2021-2032)
5 Nimodipine Sustained Release Tablets Market by Application
  1. 5.1 Nimodipine Sustained Release Tablets Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Pharmacy
  4. 5.1.3 Others
  5. 5.2 Global Nimodipine Sustained Release Tablets Sales by Application
  6. 5.2.1 Global Nimodipine Sustained Release Tablets Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Nimodipine Sustained Release Tablets Sales by Application (2021-2032)
  8. 5.2.3 Global Nimodipine Sustained Release Tablets Sales Market Share by Application (2021-2032)
  9. 5.3 Global Nimodipine Sustained Release Tablets Revenue by Application
  10. 5.3.1 Global Nimodipine Sustained Release Tablets Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Nimodipine Sustained Release Tablets Revenue by Application (2021-2032)
  12. 5.3.3 Global Nimodipine Sustained Release Tablets Revenue Market Share by Application (2021-2032)
6 Global Nimodipine Sustained Release Tablets Sales by Region
  1. 6.1 Global Nimodipine Sustained Release Tablets Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Nimodipine Sustained Release Tablets Sales by Region (2021-2032)
  3. 6.2.1 Global Nimodipine Sustained Release Tablets Sales by Region (2021-2026)
  4. 6.2.2 Global Nimodipine Sustained Release Tablets Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Nimodipine Sustained Release Tablets Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Nimodipine Sustained Release Tablets Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Nimodipine Sustained Release Tablets Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Nimodipine Sustained Release Tablets Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Nimodipine Sustained Release Tablets Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Nimodipine Sustained Release Tablets Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Nimodipine Sustained Release Tablets Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Nimodipine Sustained Release Tablets Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Nimodipine Sustained Release Tablets Revenue by Region
  1. 7.1 Global Nimodipine Sustained Release Tablets Revenue by Region
  2. 7.1.1 Global Nimodipine Sustained Release Tablets Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Nimodipine Sustained Release Tablets Revenue by Region (2021-2026)
  4. 7.1.3 Global Nimodipine Sustained Release Tablets Revenue by Region (2027-2032)
  5. 7.1.4 Global Nimodipine Sustained Release Tablets Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Nimodipine Sustained Release Tablets Revenue (2021-2032)
  8. 7.2.2 North America Nimodipine Sustained Release Tablets Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Nimodipine Sustained Release Tablets Revenue (2021-2032)
  11. 7.3.2 Europe Nimodipine Sustained Release Tablets Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Nimodipine Sustained Release Tablets Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Nimodipine Sustained Release Tablets Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Nimodipine Sustained Release Tablets Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Nimodipine Sustained Release Tablets Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Arbor Pharmaceuticals
  2. 8.1.1 Arbor Pharmaceuticals Company Information
  3. 8.1.2 Arbor Pharmaceuticals Business Overview
  4. 8.1.3 Arbor Pharmaceuticals Nimodipine Sustained Release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Arbor Pharmaceuticals Nimodipine Sustained Release Tablets Product Portfolio
  6. 8.1.5 Arbor Pharmaceuticals Recent Developments
  7. 8.2 Bayer Vital
  8. 8.2.1 Bayer Vital Company Information
  9. 8.2.2 Bayer Vital Business Overview
  10. 8.2.3 Bayer Vital Nimodipine Sustained Release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bayer Vital Nimodipine Sustained Release Tablets Product Portfolio
  12. 8.2.5 Bayer Vital Recent Developments
  13. 8.3 Bionpharma
  14. 8.3.1 Bionpharma Company Information
  15. 8.3.2 Bionpharma Business Overview
  16. 8.3.3 Bionpharma Nimodipine Sustained Release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bionpharma Nimodipine Sustained Release Tablets Product Portfolio
  18. 8.3.5 Bionpharma Recent Developments
  19. 8.4 Heritage Pharmaceuticals
  20. 8.4.1 Heritage Pharmaceuticals Company Information
  21. 8.4.2 Heritage Pharmaceuticals Business Overview
  22. 8.4.3 Heritage Pharmaceuticals Nimodipine Sustained Release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Heritage Pharmaceuticals Nimodipine Sustained Release Tablets Product Portfolio
  24. 8.4.5 Heritage Pharmaceuticals Recent Developments
  25. 8.5 Pharmaceutics International
  26. 8.5.1 Pharmaceutics International Company Information
  27. 8.5.2 Pharmaceutics International Business Overview
  28. 8.5.3 Pharmaceutics International Nimodipine Sustained Release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pharmaceutics International Nimodipine Sustained Release Tablets Product Portfolio
  30. 8.5.5 Pharmaceutics International Recent Developments
  31. 8.6 Sofgen Pharmaceuticals
  32. 8.6.1 Sofgen Pharmaceuticals Company Information
  33. 8.6.2 Sofgen Pharmaceuticals Business Overview
  34. 8.6.3 Sofgen Pharmaceuticals Nimodipine Sustained Release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Sofgen Pharmaceuticals Nimodipine Sustained Release Tablets Product Portfolio
  36. 8.6.5 Sofgen Pharmaceuticals Recent Developments
  37. 8.7 Wuhan HITECK Biopharmaceutical
  38. 8.7.1 Wuhan HITECK Biopharmaceutical Company Information
  39. 8.7.2 Wuhan HITECK Biopharmaceutical Business Overview
  40. 8.7.3 Wuhan HITECK Biopharmaceutical Nimodipine Sustained Release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Wuhan HITECK Biopharmaceutical Nimodipine Sustained Release Tablets Product Portfolio
  42. 8.7.5 Wuhan HITECK Biopharmaceutical Recent Developments
  43. 8.8 Sihuan Pharmaceutical
  44. 8.8.1 Sihuan Pharmaceutical Company Information
  45. 8.8.2 Sihuan Pharmaceutical Business Overview
  46. 8.8.3 Sihuan Pharmaceutical Nimodipine Sustained Release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Sihuan Pharmaceutical Nimodipine Sustained Release Tablets Product Portfolio
  48. 8.8.5 Sihuan Pharmaceutical Recent Developments
  49. 8.9 Jiangsu Kanion Pharmaceutical
  50. 8.9.1 Jiangsu Kanion Pharmaceutical Company Information
  51. 8.9.2 Jiangsu Kanion Pharmaceutical Business Overview
  52. 8.9.3 Jiangsu Kanion Pharmaceutical Nimodipine Sustained Release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Jiangsu Kanion Pharmaceutical Nimodipine Sustained Release Tablets Product Portfolio
  54. 8.9.5 Jiangsu Kanion Pharmaceutical Recent Developments
  55. 8.10 Qilu Pharmaceutical
  56. 8.10.1 Qilu Pharmaceutical Company Information
  57. 8.10.2 Qilu Pharmaceutical Business Overview
  58. 8.10.3 Qilu Pharmaceutical Nimodipine Sustained Release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Qilu Pharmaceutical Nimodipine Sustained Release Tablets Product Portfolio
  60. 8.10.5 Qilu Pharmaceutical Recent Developments
  61. 8.11 Shandong Yunmen Pharmaceutical
  62. 8.11.1 Shandong Yunmen Pharmaceutical Company Information
  63. 8.11.2 Shandong Yunmen Pharmaceutical Business Overview
  64. 8.11.3 Shandong Yunmen Pharmaceutical Nimodipine Sustained Release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Shandong Yunmen Pharmaceutical Nimodipine Sustained Release Tablets Product Portfolio
  66. 8.11.5 Shandong Yunmen Pharmaceutical Recent Developments
  67. 8.12 Yabao Pharmaceutical Group
  68. 8.12.1 Yabao Pharmaceutical Group Company Information
  69. 8.12.2 Yabao Pharmaceutical Group Business Overview
  70. 8.12.3 Yabao Pharmaceutical Group Nimodipine Sustained Release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Yabao Pharmaceutical Group Nimodipine Sustained Release Tablets Product Portfolio
  72. 8.12.5 Yabao Pharmaceutical Group Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Nimodipine Sustained Release Tablets Value Chain Analysis
  2. 9.1.1 Nimodipine Sustained Release Tablets Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Nimodipine Sustained Release Tablets Production Mode & Process
  6. 9.2 Nimodipine Sustained Release Tablets Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Nimodipine Sustained Release Tablets Distributors
  9. 9.2.3 Nimodipine Sustained Release Tablets Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst